Lupus & antiphospholipid syndrome
Effect of dapagliflozin on renal response in patients with biopsy-confirmed lupus nephritis receiving stable maintenance immunosuppression and renin–angiotensin system inhibition: protocol for the multicentre randomised DAPA-LN trial
Study context
- Population
- Adults with biopsy-confirmed lupus nephritis (LN) (class III or IV with or without class V involvement, or pure class V), persistent proteinuria (urine protein-to-creatinine ratio >0.5 and ≤ 3.5 g/g) and an estimated glomerular filtration rate ≥30 mL/min/1.73 m², at seven hospitals in Chinaplanned total to be randomly assigned
- Participants
- 270 adults
- Planned comparison
- Dapagliflozin 10 mg once daily plus standard background therapy or standard background therapy alone
- Primary endpoint
- Renal response, defined by prespecified improvement in proteinuria together with preservation of kidney function
- Follow-up
- Week 52
Methodological detailsprotocol, 1:1 randomisation, intention-to-treat primary efficacy analysis
- Protocol
- 1:1 randomisation
- Intention-to-treat primary efficacy analysis
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Effect of dapagliflozin on renal response in patients with biopsy-confirmed lupus nephritis receiving stable maintenance immunosuppression and renin–angiotensin system inhibition: protocol for the multicentre randomised DAPA-LN trial. Lupus Sci Med. Published 28 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →